NorthWest Biotherapeutics Inc (NWBO)

[Maverick0408]

Merck will certainly not pay $20B for GBM indication alone. That sort of valuation just doesn’t make sense as it’s a relatively modest market size. So LP will have to sell Merck on the platform technology with key observations from ph 1 Direct trial and the broad applicability of both L & Direct. Hopefully, they will also have some data from their combo trial later this year. That could potentially pave way for similar combo trials in other areas and extending the shelf life of Keytruda in some way.